(2-chloro-5-nitrophenyl)(4-(4-methoxyphenyl)piperazin-1-yl)methanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (2-chloro-5-nitrophenyl)(4-(4-methoxyphenyl)piperazin-1-yl)methanone
• 英文别名: 1-(2-chloro-5-nitrobenzoyl)-4-(4-methoxyphenyl)piperazine；(2-chloro-5-nitrophenyl)-[4-(4-methoxyphenyl)piperazin-1-yl]methanone
• 化学式: C₁₈H₁₈ClN₃O₄
• mdl: MFCD03032063
• 分子量: 375.812
• InChiKey: OHNBAVSOHRRXFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  78.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-(4-甲氧基苯基)哌嗪 、 2-氯-5-硝基苯甲酸 在 EDC-polymer 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以56%的产率得到(2-chloro-5-nitrophenyl)(4-(4-methoxyphenyl)piperazin-1-yl)methanone
  参考文献：
  名称：

  Discovery of halo-nitrobenzamides with potential application against human African trypanosomiasis

  摘要：

  A series of halo-nitrobenzamide were synthesized and evaluated for their ability to block proliferation of Trypanosoma brucei brucei. A number of these compounds had significant activity against the parasite, particularly 2-chloro-N-(4-chlorophenyl)-5-nitrobenzamide 17 which exhibited low micromolar inhibitory potency against T. brucei and selectivity towards both malaria and mammalian cells. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.022

文献信息

• Substituted acylpiperazine derivatives
  申请人：Alberati-Giani Daniela

  公开号：US20050059668A1

  公开（公告）日：2005-03-17

  The invention relates to compounds of formula wherein the substituents are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention further relates to methods for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

  该发明涉及以下式中的化合物，其中取代基如规范中定义，并且其药用可接受的酸盐。该发明还涉及治疗精神病、疼痛、记忆和学习中的神经退行性功能障碍、精神分裂症、痴呆症以及其他认知过程受损的疾病的方法，如注意力缺陷障碍或阿尔茨海默病。
• 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1703909A1

  公开（公告）日：2006-09-27
• JP2007505062A
  申请人：——

  公开号：JP2007505062A

  公开（公告）日：2007-03-08
• US7462617B2
  申请人：——

  公开号：US7462617B2

  公开（公告）日：2008-12-09
• [EN] 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES<br/>[FR] DERIVES DE 1-BENZOYL-PIPERAZINE COMME INHIBITEURS DU RECAPTAGE DE LA GLYCINE POUR LE TRAITEMENT DE PSYCHOSES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005023261A1

  公开（公告）日：2005-03-17

  The invention relates to compounds of formula (I) wherein Ar is substituted aryl or unsubstituted or substituted 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, CN, (C1­C6)-alkyl, (C1-C6)-alkyl substituted by halogen, (C1-C6)-alkoxy, (C1-C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10; R1 is hydrogen or (C1-C6)-alkyl; R2 is halogen, (C1-C6) -alkyl, (C2-C6) -alkenyl, wherein a hydrogen atom may be replaced by CN, C(O)-R9 or (C1-C6)-alkyl, or is (C2-C6)­alkynyl, (C1-C6)-alkyl substituted by halogen, -(CH2)n-(C3-C7)-cycloalkyl, -(CH2)n-heterocycloalkyl, -C(O)-R9, -(CH2)n-aryl or -(CH2)n-5 or -6­membered heteroaryl containing one, two or three heteroatoms, selected from the group consisting of oxygen, sulphur or nitrogen wherein aryl, cycloalkyl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, (C1-C6)-alkyl, (C1-C6)-alkyl substituted by halogen or (C1-C6) alkoxy; R3, R4 and R6 independently from each other are hydrogen, hydroxy, halogen, (C1-C6)-alkyl or (C1-C6)-alkoxy; R5 is NO2, CN, C(O)R9, SO2R10 or NR11R12 ; R7 and R8 independently from each other are hydrogen or (C1-C6)-alkyl; the other substituents are defined in the claims; and to pharmaceutically acceptable acid addition salts thereof for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.